Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Samil Pharmaceutical Co. Ltd. (000520:KRX), powered by AI.
Samil Pharmaceutical Co. Ltd. is currently trading at ₩8,890. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Samil Pharmaceutical Co. Ltd. on Alpha Lenz.
Samil Pharmaceutical Co. Ltd.'s P/E ratio is -28.4.
“Samil Pharmaceutical Co. Ltd. trades at a P/E of -28.4 (undervalued) with modest ROE of -3.7%. 3Y revenue CAGR of 17.8% highlights clear growth momentum.”
Ask for details →Samil Pharmaceutical Co. Ltd. is a key player in the pharmaceutical industry, primarily focusing on the research, development, and distribution of a diverse range of medical products. The company's portfolio spans prescription medications, over-the-counter drugs, and various pharmaceutical solutions that serve multiple therapeutic areas. Samil Pharmaceutical is committed to advancing healthcare by leveraging innovation to create effective and safe medicinal products. Operating within a highly regulated sector, the company addresses critical healthcare needs and partners with both domestic and international healthcare providers to ensure accessibility and effectiveness of treatments. Samil's role in the market is significant, contributing to advancements in therapeutic solutions and improving patient outcomes. As part of the broader pharmaceutical ecosystem, the company collaborates with research institutions and other industry stakeholders to foster advancements in medical science and enhance the overall health of communities globally.
“Samil Pharmaceutical Co. Ltd. trades at a P/E of -28.4 (undervalued) with modest ROE of -3.7%. 3Y revenue CAGR of 17.8% highlights clear growth momentum.”
Ask for details →Samil Pharmaceutical Co. Ltd. (ticker: 000520) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 583 employees. Market cap is $192.8B.
The current price is ₩8,890 with a P/E ratio of -28.4x and P/B of 0.91x.
ROE is -3.70% and operating margin is 0.05%. Annual revenue is $219.7B.